Fundamental and clinical evaluation of ceftriaxone in the pediatric field

K. Sunakawa, N. Saitoh, A. Adachibara, Y. Ishizuka, S. Iwata, Y. Satoh, H. Akita

Research output: Contribution to journalArticle

Abstract

Fundamental and clinical evaluation of ceftriaxone (CTRX) was performed in the pediatric field and the following results were obtained. 1. The MIC of CTRX against E. coli isolated from urinary tract infections in children ranged from ≤0.024 to 0.39 mcg/ml except for 1 strain. CTRX was superior to other 3rd generation cephalosporins such as CPZ and LMOX, showing effectiveness also against ABPC-resistant bacteria. 2. The clinical efficacy and bacteriological efficacy in 6 children consisting of 5 with respiratory tract infections and 1 with a urinary tract infection were 83% and 100%, respectively. As to the adverse reaction, diarrhea was observed in 2 cases. 3. The determination of PIVKA-II performed during the therapy with CTRX, which is observed when vitamin K is deficient, was positive in 2 out of 6 cases including 1 in which the clinical efficacy could not be evaluated. The test of platelet function in 3 cases found no inhibition of agglutination. Twice-daily administration with 20 mg/kg CTRX was considered to be a useful and safe method for treatment of bacterial infections in children, although care should be taken not to cause vitamin K deficiency as in other 2nd and 3rd generation cephalosporins.

Original languageEnglish
Pages (from-to)2102-2110
Number of pages9
JournalJapanese Journal of Antibiotics
Volume37
Issue number11
Publication statusPublished - 1984
Externally publishedYes

Fingerprint

Ceftriaxone
Pediatrics
Cephalosporins
Urinary Tract Infections
Platelet Function Tests
Vitamin K Deficiency
Vitamin K
Agglutination
Child Care
Bacterial Infections
Respiratory Tract Infections
Diarrhea
Escherichia coli
Bacteria
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Sunakawa, K., Saitoh, N., Adachibara, A., Ishizuka, Y., Iwata, S., Satoh, Y., & Akita, H. (1984). Fundamental and clinical evaluation of ceftriaxone in the pediatric field. Japanese Journal of Antibiotics, 37(11), 2102-2110.

Fundamental and clinical evaluation of ceftriaxone in the pediatric field. / Sunakawa, K.; Saitoh, N.; Adachibara, A.; Ishizuka, Y.; Iwata, S.; Satoh, Y.; Akita, H.

In: Japanese Journal of Antibiotics, Vol. 37, No. 11, 1984, p. 2102-2110.

Research output: Contribution to journalArticle

Sunakawa, K, Saitoh, N, Adachibara, A, Ishizuka, Y, Iwata, S, Satoh, Y & Akita, H 1984, 'Fundamental and clinical evaluation of ceftriaxone in the pediatric field', Japanese Journal of Antibiotics, vol. 37, no. 11, pp. 2102-2110.
Sunakawa K, Saitoh N, Adachibara A, Ishizuka Y, Iwata S, Satoh Y et al. Fundamental and clinical evaluation of ceftriaxone in the pediatric field. Japanese Journal of Antibiotics. 1984;37(11):2102-2110.
Sunakawa, K. ; Saitoh, N. ; Adachibara, A. ; Ishizuka, Y. ; Iwata, S. ; Satoh, Y. ; Akita, H. / Fundamental and clinical evaluation of ceftriaxone in the pediatric field. In: Japanese Journal of Antibiotics. 1984 ; Vol. 37, No. 11. pp. 2102-2110.
@article{4db76a6f3c5440009736bb4db13d6948,
title = "Fundamental and clinical evaluation of ceftriaxone in the pediatric field",
abstract = "Fundamental and clinical evaluation of ceftriaxone (CTRX) was performed in the pediatric field and the following results were obtained. 1. The MIC of CTRX against E. coli isolated from urinary tract infections in children ranged from ≤0.024 to 0.39 mcg/ml except for 1 strain. CTRX was superior to other 3rd generation cephalosporins such as CPZ and LMOX, showing effectiveness also against ABPC-resistant bacteria. 2. The clinical efficacy and bacteriological efficacy in 6 children consisting of 5 with respiratory tract infections and 1 with a urinary tract infection were 83{\%} and 100{\%}, respectively. As to the adverse reaction, diarrhea was observed in 2 cases. 3. The determination of PIVKA-II performed during the therapy with CTRX, which is observed when vitamin K is deficient, was positive in 2 out of 6 cases including 1 in which the clinical efficacy could not be evaluated. The test of platelet function in 3 cases found no inhibition of agglutination. Twice-daily administration with 20 mg/kg CTRX was considered to be a useful and safe method for treatment of bacterial infections in children, although care should be taken not to cause vitamin K deficiency as in other 2nd and 3rd generation cephalosporins.",
author = "K. Sunakawa and N. Saitoh and A. Adachibara and Y. Ishizuka and S. Iwata and Y. Satoh and H. Akita",
year = "1984",
language = "English",
volume = "37",
pages = "2102--2110",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "11",

}

TY - JOUR

T1 - Fundamental and clinical evaluation of ceftriaxone in the pediatric field

AU - Sunakawa, K.

AU - Saitoh, N.

AU - Adachibara, A.

AU - Ishizuka, Y.

AU - Iwata, S.

AU - Satoh, Y.

AU - Akita, H.

PY - 1984

Y1 - 1984

N2 - Fundamental and clinical evaluation of ceftriaxone (CTRX) was performed in the pediatric field and the following results were obtained. 1. The MIC of CTRX against E. coli isolated from urinary tract infections in children ranged from ≤0.024 to 0.39 mcg/ml except for 1 strain. CTRX was superior to other 3rd generation cephalosporins such as CPZ and LMOX, showing effectiveness also against ABPC-resistant bacteria. 2. The clinical efficacy and bacteriological efficacy in 6 children consisting of 5 with respiratory tract infections and 1 with a urinary tract infection were 83% and 100%, respectively. As to the adverse reaction, diarrhea was observed in 2 cases. 3. The determination of PIVKA-II performed during the therapy with CTRX, which is observed when vitamin K is deficient, was positive in 2 out of 6 cases including 1 in which the clinical efficacy could not be evaluated. The test of platelet function in 3 cases found no inhibition of agglutination. Twice-daily administration with 20 mg/kg CTRX was considered to be a useful and safe method for treatment of bacterial infections in children, although care should be taken not to cause vitamin K deficiency as in other 2nd and 3rd generation cephalosporins.

AB - Fundamental and clinical evaluation of ceftriaxone (CTRX) was performed in the pediatric field and the following results were obtained. 1. The MIC of CTRX against E. coli isolated from urinary tract infections in children ranged from ≤0.024 to 0.39 mcg/ml except for 1 strain. CTRX was superior to other 3rd generation cephalosporins such as CPZ and LMOX, showing effectiveness also against ABPC-resistant bacteria. 2. The clinical efficacy and bacteriological efficacy in 6 children consisting of 5 with respiratory tract infections and 1 with a urinary tract infection were 83% and 100%, respectively. As to the adverse reaction, diarrhea was observed in 2 cases. 3. The determination of PIVKA-II performed during the therapy with CTRX, which is observed when vitamin K is deficient, was positive in 2 out of 6 cases including 1 in which the clinical efficacy could not be evaluated. The test of platelet function in 3 cases found no inhibition of agglutination. Twice-daily administration with 20 mg/kg CTRX was considered to be a useful and safe method for treatment of bacterial infections in children, although care should be taken not to cause vitamin K deficiency as in other 2nd and 3rd generation cephalosporins.

UR - http://www.scopus.com/inward/record.url?scp=0021748733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021748733&partnerID=8YFLogxK

M3 - Article

C2 - 6098704

AN - SCOPUS:0021748733

VL - 37

SP - 2102

EP - 2110

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 11

ER -